This is devoted to the modeling of tumor drug resistance, and more precisely with the case of gastrointestinal stromal tumor (GIST) liver metastases that are resistant to two standard treatments based on tyrosine kinase inhibitors: imatinib and sunitinib. Using an accurate analysis of medical images, we have built a patient-dependent model, which is a non linear system of partial differential equations, that reproduces qualitatively and quantitatively the spatial tumor evolution as well as the tumor volume evolution as followed up by the clinical data, for one specific patient. Moreover, specific aspects of tumor growth such as the spatial heterogeneity and treatment failures can be explained by our model. We show numerically that the spatial structure of the tumor can provide more insights on the cancer cell activity than the standard RECIST criteria, which only consists
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